Mirum SVP sells 2,594 shares in pre-planned trade

Mirum Pharmaceuticals SVP Jolanda Howe reported an open-market sale of 2,594 shares of Common Stock at $101.95 per share.

Rhea-AI Filing Summary

Mirum Pharmaceuticals SVP Jolanda Howe reported an open-market sale of 2,594 shares of Common Stock at $101.95 per share. After this transaction, she directly holds 5,835 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating the timing was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 2,594 shares

Net Sell 1 txn

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 2,594 shs ($264K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,594	$101.95	$264K

Holdings After Transaction: Common Stock — 5,835 shares (Direct)

Footnotes (1)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

Key Figures

Shares sold: 2,594 shares Sale price: $101.95 per share Shares owned after sale: 5,835 shares +2 more

5 metrics

Shares sold 2,594 shares Open-market sale of Common Stock

Sale price $101.95 per share Price for the 2,594 shares sold

Shares owned after sale 5,835 shares Direct holdings following transaction

Transaction code S Sale in open market or private transaction

Plan adoption date March 18, 2026 Rule 10b5-1 Plan adoption for this trade

Key Terms

Rule 10b5-1 Plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: "open-market sale" and transaction_code_description: "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" in the reported Form 4 transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mirum Pharmaceuticals (MIRM) report for Jolanda Howe?

Mirum Pharmaceuticals reported that SVP and Global Controller Jolanda Howe completed an open-market sale of 2,594 shares of Common Stock at $101.95 per share. Following this transaction, she directly holds 5,835 shares in the company.

At what price were the Mirum (MIRM) shares sold in Jolanda Howe’s Form 4 filing?

The reported transaction shows an open-market sale at $101.95 per share. This price applies to the 2,594 shares of Mirum Pharmaceuticals Common Stock sold by SVP and Global Controller Jolanda Howe in the disclosed Form 4 transaction.

How many Mirum Pharmaceuticals (MIRM) shares does Jolanda Howe hold after the reported sale?

After the reported sale, Jolanda Howe directly holds 5,835 shares of Mirum Pharmaceuticals Common Stock. This post-transaction holding is disclosed in the Form 4 as the total number of shares beneficially owned following the open-market sale.

Was Jolanda Howe’s Mirum (MIRM) stock sale part of a Rule 10b5-1 trading plan?

Yes. The footnote states the transaction occurred under a Rule 10b5-1 Plan adopted on March 18, 2026. Such plans pre-schedule trades, meaning the timing of this 2,594-share sale was arranged in advance.

What type of transaction is disclosed in the Mirum (MIRM) Form 4 for Jolanda Howe?

The Form 4 describes the event as an open-market sale of Common Stock, coded as an “S” transaction. It covers the sale of 2,594 shares at $101.95 per share, with direct ownership reported after the trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 06:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S(1)		2,594	D	$101.95	5,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

	/s/ Doug Sheehy, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)